Physician profile
John E Rooney
NPI 1104811421
$379.86
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170 · 2020: $17.23 · 2021: $173 · 2022: $19.49.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $54.24 | 2021 | |
| Genzyme Corporation | $54.15 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $40.99 | 2019-2021 | |
| Circassia INC. | $38.64 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $33.66 | 2019-2020 | |
| Octapharma USA, INC. | $30.02 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $26.01 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $16.00 | 2019 | |
| Kaleo, INC. | $15.74 | 2019 | |
| Sanofi Pasteur INC. | $14.84 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.33 | 2021 | |
| Glaxosmithkline, LLC. | $11.60 | 2021 | |
| Pfizer INC. | $11.15 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Rooney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.